Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Liposarcoma, Myxoid 1Graft vs Host Disease 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 8avelumab 6fludarabine 3Radiotherapy 3Radiation 3Cyclophosphamide 3cemiplimab 2atezolizumab 2aldesleukin 2Interleukin-2 2Interferon-beta 2ALT-803 2talimogene laherparepvec 1poly ICLC 1pentetreotide 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1cabozantinib 1bempegaldesleukin 1TTI-621 1Paclitaxel 1Nivolumab 1Interferon-gamma 1Influenza Vaccines 1Immunotherapy 1High-Intensity Focused Ultrasound Ablation 1Carboxylesterase 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Merkel Cell × Interferon-gamma × Clear all
NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
7 enrolled 15 charts
Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡